Medicines Patent Pool

medicinespatentpool.org

The Medicines Patent Pool is a United Nations-backed public health organisation working to increase access to HIV, viral hepatitis C and tuberculosis treatments in low- and middle-income countries. The MPP partners with civil society, international organisations, industry, patient groups and other stakeholders to priorities, forecast and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Research

ADARE PHARMA SOLUTIONS ANNOUNCES DIVESTITURE OF POSTBIOTICS PIONEER ADARE BIOME TO DSM-FIRMENICH

prnewswire | July 04, 2023

news image

Adare Pharma Solutions, a global technology-driven CDMO focused on oral dosage forms, today announced the completion of its divestiture of its Adare Biome business unit, a pioneer in the development and manufacturing of postbiotics, to dsm-firmenich, innovators in nutrition, health, and beauty. The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x. Tom Sellig, CEO of Adare Pharma Solutions, commented: "dsm-firmenich...

Read More

Views and Analysis

ENTERIS BIOPHARMA PUBLISHES WHITE PAPER EXAMINING FACTORS TO CONSIDER WHILE EVALUATING ORAL ADMINISTRATION OF PEPTIDES

Enteris BioPharma | September 13, 2022

news image

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation announced the publication of a new white paper in Drug Development & Delivery entitled, "Key Considerations in Oral Delivery of Peptides – Factors to Consider While Evaluating Oral Administration." The paper, authored by John Vrettos, PhD, Director of Formulation Developmen...

Read More

Pharma Tech

NUCLEAI ANNOUNCES A PARTNERSHIP WITH SIRONA DX FOR AI-DRIVEN DISCOVERY OF NOVEL SPATIAL BIOMARKERS IN SOLID TUMORS

Nucleai and Sirona Dx | July 14, 2022

news image

Nucleai, a leader in AI-powered spatial biology transforming precision medicine by unlocking the power of pathology data, and Sirona Dx, a leading provider of multiomic single-cell analytical services, today announced a collaboration to advance the discovery of novel spatial biomarkers in solid tumors. The partnership combines Nucleai’s powerful AI spatial analytics platform with Sirona Dx’s leading multiplex assay development expertise to identify novel spatial signatures in high-pl...

Read More

PHARMACY MARKET

CYTEL CONTINUES EXPANSION OF MARKET ACCESS AND MEDICAL COMMUNICATION CAPABILITIES WITH THE ACQUISITION OF CO.FAKTOR

Business Wire | September 28, 2023

news image

Cytel Inc., provider of quantitative insights and health data analytics to leaders in the life sciences, has acquired the Berlin-based company co.faktor GmbH with its dedicated healthcare consultancy services co.value® (market access), co.medical® (medical communications), and co.patient® (patient relations) concentrations. As a result, Cytel’s services for biopharma commercializa...

Read More
news image

Research

ADARE PHARMA SOLUTIONS ANNOUNCES DIVESTITURE OF POSTBIOTICS PIONEER ADARE BIOME TO DSM-FIRMENICH

prnewswire | July 04, 2023

Adare Pharma Solutions, a global technology-driven CDMO focused on oral dosage forms, today announced the completion of its divestiture of its Adare Biome business unit, a pioneer in the development and manufacturing of postbiotics, to dsm-firmenich, innovators in nutrition, health, and beauty. The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x. Tom Sellig, CEO of Adare Pharma Solutions, commented: "dsm-firmenich...

Read More
news image

Views and Analysis

ENTERIS BIOPHARMA PUBLISHES WHITE PAPER EXAMINING FACTORS TO CONSIDER WHILE EVALUATING ORAL ADMINISTRATION OF PEPTIDES

Enteris BioPharma | September 13, 2022

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation announced the publication of a new white paper in Drug Development & Delivery entitled, "Key Considerations in Oral Delivery of Peptides – Factors to Consider While Evaluating Oral Administration." The paper, authored by John Vrettos, PhD, Director of Formulation Developmen...

Read More
news image

Pharma Tech

NUCLEAI ANNOUNCES A PARTNERSHIP WITH SIRONA DX FOR AI-DRIVEN DISCOVERY OF NOVEL SPATIAL BIOMARKERS IN SOLID TUMORS

Nucleai and Sirona Dx | July 14, 2022

Nucleai, a leader in AI-powered spatial biology transforming precision medicine by unlocking the power of pathology data, and Sirona Dx, a leading provider of multiomic single-cell analytical services, today announced a collaboration to advance the discovery of novel spatial biomarkers in solid tumors. The partnership combines Nucleai’s powerful AI spatial analytics platform with Sirona Dx’s leading multiplex assay development expertise to identify novel spatial signatures in high-pl...

Read More
news image

PHARMACY MARKET

CYTEL CONTINUES EXPANSION OF MARKET ACCESS AND MEDICAL COMMUNICATION CAPABILITIES WITH THE ACQUISITION OF CO.FAKTOR

Business Wire | September 28, 2023

Cytel Inc., provider of quantitative insights and health data analytics to leaders in the life sciences, has acquired the Berlin-based company co.faktor GmbH with its dedicated healthcare consultancy services co.value® (market access), co.medical® (medical communications), and co.patient® (patient relations) concentrations. As a result, Cytel’s services for biopharma commercializa...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us